A randomised controlled double‐blind clinical trial of 17‐hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity

Publisher： John Wiley & Sons Inc

E-ISSN： 1471-0528|122|1|71-79

ISSN： 1470-0328

Source： BJOG : AN INTERNATIONAL JOURNAL OF OBSTETRICS & GYNAECOLOGY, Vol.122, Iss.1, 2015-01, pp. : 71-79

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

17-α hydroxyprogesterone caproate for the prevention of preterm birth

By Gupta Simi   Roman Ashley S  

Women's Health, Vol. 8, Iss. 1, 2012-01 ,pp. : 21-30

Future Medicine

Access to resources Recommend Favorite

The role of 17 α-hydroxyprogesterone caproate in the prevention of preterm birth

By Meis Paul J  

Women's Health, Vol. 2, Iss. 6, 2006-11 ,pp. : 819-824

Future Medicine

Access to resources Recommend Favorite

Prevention of preterm delivery with vaginal progesterone in women with preterm labour (4P): randomised double‐blind placebo‐controlled trial

By  

BJOG : AN INTERNATIONAL JOURNAL OF OBSTETRICS & GYNAECOLOGY, Vol. 122, Iss. 1, 2015-01 ,pp. : 80-91

John Wiley & Sons Inc

Access to resources Recommend Favorite

Is 17α‐hydroxyprogesterone caproate contraindicated in twin gestations?

By  

BJOG : AN INTERNATIONAL JOURNAL OF OBSTETRICS & GYNAECOLOGY, Vol. 122, Iss. 1, 2015-01 ,pp. : 6-7

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacogenomics of 17‐alpha hydroxyprogesterone caproate for recurrent preterm birth: a case–control study

By  

BJOG : AN INTERNATIONAL JOURNAL OF OBSTETRICS & GYNAECOLOGY, Vol. 125, Iss. 3, 2018-02 ,pp. : 343-350

John Wiley & Sons Inc

Access to resources Recommend Favorite